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Key questions
What is already known?
 ► Vaccination is the most cost-effective public health 
intervention against infectious diseases.
 ► Several sub-Saharan African countries continue to 
lag significantly behind recommended global vac-
cine coverage and equity targets despite having the 
highest burdens of vaccine-preventable diseases.
What are the new findings?
 ► Between 2000 and 2009, West African countries 
made significant strides at increasing national 
immunisation coverages and retaining children 
who commenced vaccination in the immunisation 
system.
 ► Coverages have plateaued in most countries since 
2009 after an initial rapid increase.
 ► As of 2017, Burkina Faso, Cabo Verde, The Gambia, 
Ghana, Senegal, Sierra Leone and Togo out of the 15 
West African countries had met the Global Vaccine 
Action Plan (GVAP) targets of third dose of diphthe-
ria–tetanus–pertussis coverage of 90% or more.
 ► Guinea, Mali and Nigeria had the widest equity gaps 
in immunisation in West Africa, with inequalities in 
coverages and dropouts mostly related to poverty, 
low maternal education and living in certain disad-
vantaged regions within a country.
What do the new findings imply?
 ► Countries with low vaccination coverages and wide 
equity gaps in West Africa could strengthen their im-
munisation systems by adopting useful lessons and 
local solutions from their peers in the subregion who 
have achieved and sustained the GVAP targets on 
coverages and equity.
 ► Continued government commitment and investment 
in the subregion will be pivotal in reaching the chil-
dren who are ‘left behind’, reducing equity gaps, 
and ensuring that hard-won gains are maintained 
especially with some Gavi-eligible countries sched-
uled for graduation from Gavi support in the coming 
years.
ABSTRACT
Background Several West African countries are unlikely 
to achieve the recommended Global Vaccine Action Plan 
(GVAP) immunisation coverage and dropout targets in a 
landscape beset with entrenched intra-country equity gaps 
in immunisation. Our aim was to assess and compare the 
immunisation coverage, dropout and equity gaps across 15 
West African countries between 2000 and 2017.
Methods We compared Bacille Calmette Guerin (BCG) 
and the third dose of diphtheria–tetanus–pertussis 
(DTP3) containing vaccine coverage between 2000 and 
2017 using the WHO and Unicef Estimates of National 
Immunisation Coverage for 15 West African countries. 
Estimated subregional median and weighted average 
coverages, and dropout (DTP1–DTP3) were tracked against 
the GVAP targets of ≥90% coverage (BCG and DTP3), 
and ≤10% dropouts. Equity gaps in immunisation were 
assessed using the latest disaggregated national health 
survey immunisation data.
Results The weighted average subregional BCG coverage 
was 60.7% in 2000, peaked at 83.2% in 2009 and was 
65.7% in 2017. The weighted average DTP3 coverage was 
42.3% in 2000, peaked at 70.3% in 2009 and was 61.5% 
in 2017. As of 2017, 46.7% of countries (7/15) had met 
the GVAP targets on DTP3 coverage. Average weighted 
subregional immunisation dropouts consistently reduced 
from 16.4% in 2000 to 7.4% in 2017, meeting the GVAP 
target in 2008. In most countries, inequalities in BCG, and 
DTP3 coverage and dropouts were mainly related to equity 
gaps of more than 20% points between the wealthiest 
and the poorest, high coverage regions and low coverage 
regions, and between children of mothers with at least 
secondary education and those with no formal education. 
A child’s sex and place of residence (urban or rural) 
minimally determined equity gaps.
Conclusions The West African subregion made progress 
between 2000 and 2017 in ensuring that its children 
utilised immunisation services, however, wide equity gaps 
persist.
BACKgRound
Vaccination is the most cost-effective interven-
tion for the control of infectious diseases.1 Not 
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only has vaccination reduced the burden and severity of 
vaccine preventable diseases (VPDs) such as measles and 
tuberculosis, but its use resulted in the eradication of 
smallpox in 1978.2 Similarly, poliomyelitis is on the verge of 
eradication, with only 29 reported cases of wild poliovirus 
across two countries globally in 2018 compared with an esti-
mated 350 000 cases in 125 endemic countries in 1988.3 4 
Despite this progress and the introduction of an increasing 
number of vaccines to the Expanded Programme on 
Immunisation, many children continue to go unvaccinated 
by their first birthday or never complete the recommended 
schedule.5 For example, in 2017, an estimated 19.9 million 
children globally did not receive the third dose of diph-
theria–tetanus–pertussis-containing vaccine (including 
DTP3 and Penta3, but henceforth DTP3).6
Vaccination has equally been demonstrated to be a 
cost-effective intervention for disease control. For example, 
it is estimated that every dollar spent on immunisation 
yields more than 16 times return on investment (ROI) and 
when other broader benefits of vaccination are considered, 
the ROI rises to 48 times the cost of vaccination.7 Recog-
nising its role in global health security and the cost-effec-
tiveness of vaccination, in 2010, the WHO launched the 
Global Vaccine Action Plan (GVAP) aimed at ensuring that 
all countries worldwide achieve a DTP3 coverage of 90% 
by 2020 among other targets.8 The 2018 GVAP assessment 
report did, however, reveal that despite a global trend of 
increasing immunisation coverages rates, the achievement 
of these immunisation coverage indicators lagged behind, 
especially in low-income and middle-income countries of 
sub-Saharan Africa and South East Asia.1
In sub-Saharan Africa, particularly in West Africa, immu-
nisation system performance and vaccination coverage rates 
are lower than in other regions of the world despite having 
the highest burden of VPDs.9 Additionally, entrenched 
intra-country equity gaps in immunisation systems, a situa-
tion characterised by marked differences in access and util-
isation of immunisation services across several social and 
economic determinants of health, exist in West Africa.9 
In this landscape, a subgroup of the most vulnerable, and 
disadvantaged population in whom an increase in vacci-
nation uptake is necessary to ensure optimal reduction in 
VPD burdens will continue to be left behind. If these trends 
continue, hard-won gains in reducing VPD-related under-5 
mortality may be halted and reversed, with a significant risk 
of resurgence of previously controlled infectious diseases. 
Understanding existing inequality gaps will be pivotal to 
designing effective strategies to address the needs of disad-
vantaged subgroups and track progress made towards 
achieving global targets.
In a landscape of high VPD burden and a lagging trajec-
tory in achieving the global immunisation targets, Gavi, 
the Vaccine Alliance is the primary external source of assis-
tance for immunisation in most countries of the West Africa 
subregion, supporting the introduction of new vaccines, 
and strengthening immunisation systems to improve the 
performance.10 By unpacking the immunisation system 
performance through the lens of coverage and equity and 
tracing the trajectory prior to and after the GVAP targets 
were introduced, we wish to highlight the key areas across 
and within West Africa that would benefit from govern-
ments’ and development partners’ attention. In this article, 
we assessed and compared the immunisation coverage, 
dropout and equity gaps across 15 West African countries 
between 2000 and 2017 in relation to the GVAP targets.
MeTHodS
Study setting and context
This paper set out to analyse the immunisation system 
performance between 2000 and 2017 across 15 West 
African countries whose combined estimated population 
in 2017 was about 372 million.11 In 2017, the countries had 
an estimated total birth cohort and surviving infant popula-
tion of 13 921 000 and 13 111 000, respectively (figure 1).12
The West Africa subregion has a regional alliance, the 
Economic Community of West African States (ECOWAS) 
aimed at promoting integration in all fields of activity, 
including the health of the constituting countries. The 
West African Health Organisation (WAHO) is a special-
ised institution of ECOWAS responsible for health-re-
lated issues in the subregion. The ECOWAS is made 
up of 15-member countries including Benin, Burkina 
Faso, Cabo Verde, Cote d’ Ivoire, The Gambia, Ghana, 
Guinea, Guinea Bissau, Liberia, Mali, Niger, Nigeria, 
Senegal, Sierra Leone and Togo who have cultural and 
geopolitical ties, and shared economic interest.11 Ten of 
these fifteen countries were low-income countries with 
Gross National Income (GNI) per capita of $995 or less, 
whereas Cabo Verde, Cote d’Ivoire, Ghana, Nigeria and 
Senegal were lower-middle-income countries with GNI 
per capita of between $996 and 3895 based on the 2017 
World Bank fiscal year classification.13
Study design
We examined publicly available secondary data on 
Bacille Calmette Guerin (BCG), and DTP3 immunisation 
coverage, DTP1–DTP3 dropout rates and intra-country 
equity gaps, between 2010 and 2017 across 15 ECOWAS 
West African countries.
Patient and public involvement
This was an analysis of publicly available secondary data 
and did not involve primary patients or study participants 
in the development of the study question, study design or 
conduct of the study.
ethical approval
As this study was based purely on secondary analysis of data 
and involved no primary data collection involving patients 
or vulnerable groups, ethical approval was neither required 
nor sought. The ethical procedures for the secondary 
data used were the responsibilities of the institutions that 
commissioned, funded or managed the surveys utilised. 
The protocol for Demographic Health Survey (DHS) 
was reviewed and approved by ICF Institutional Review 
Board, and each host country’s ethics board prior to the 
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Figure 1 TreeMap showing thedistribution of the 13,111,000 estimated surviving infants’ populationacross West Africa in 
2017. (Source: Developed by authors based on UNpopulation estimates of surviving infants for 2017). *Cabo Verde.
commencement of the surveys.14 The Multiple Indicator 
Cluster Survey (MICS) survey protocols were reviewed by 
country-level ethics review boards and approved according 
to the laws in each host country.15 Additionally, DHS 
and MICS reports that survey respondents gave written 
informed consent before participation.
Measuring immunisation coverage, dropout, and equity
Immunisation systems performance is measured via 
multiple dimensions, including immunisation coverage, 
immunisation dropout, equity of coverage, the complete-
ness of vaccines in the national schedule compared with 
recommended vaccines and other administrative indica-
tors.16 In this paper, we measured immunisation coverage 
using BCG immunisation coverage and DTP3 immuni-
sation coverage. Immunisation dropout was assessed by 
measuring the DTP1 to DTP3 dropout rates.
To evaluate levels of inequality in immunisation 
coverage, we stratified the immunisation coverage 
by socioeconomic and geographic determinants of 
inequality. These include (i) child’s sex; (ii) location of 
residence; (iii) maternal education; (iv) regions within a 
country and (v) wealth quintile according to the frame-
work of the WHO Commission on Social Determinants 
of Health.17 Although the framework considers other 
dimensions such as ethnicity, migration status and other 
intermediate determinants, we were not able to include 
these indicators in the analyses because they are not 
routinely captured in national survey data.
data sources
National BCG and DTP3 vaccination coverage esti-
mates were obtained from country-specific WHO and 
Unicef Estimates of National Immunisation Coverage 
(WUENIC) data for all 15 countries.18 The data extracted 
covered a period beginning from one-decade pre-GVAP 
(2000) up until the most current country-specific data as 
of December 2018. National and regional estimates of 
birth cohort and the number of surviving infants were 
computed using the UN Population Division population 
estimates, 2017 revision, which are comparable to the 
estimates available in WUENIC databases.12
To determine equity gaps in vaccination coverage, 
we searched the publicly available UNICEF-supported 
MICS and the USAID-supported DHS databases for each 
country’s most recent final report of either household 
surveys as of December 2018.19 20 The MICS and DHS are 
nationally representative, large-scale and standardised 
household surveys, whose methodologies allow for direct 
comparisons of their data. They collect and report disag-
gregated health data, including immunisation coverages 
by several socioeconomic or geographical determinants 
of inequality including wealth quintile, maternal educa-
tion, location of residence, regions within a country and 
child’s sex.21 The detailed methodologies of MICS and 
DHS are described elsewhere.21
data analysis
The data generated after abstraction from the various 
data sources were entered into and analysed descriptively 
using Microsoft Excel (2016).
Estimating BCG immunisation coverage
BCG immunisation coverage was estimated as the 
percentage of children 12–23 months in each country who 
had received BCG.16 We calculated the median, and the 
average subregional coverage weighted by each country’s 
corresponding annual birth cohort population from 2000 
to 2017. BCG coverage was selected as an indicator as it is 
considered a key determinant of access to health services.22
Furthermore, we illustrated the highest and lowest 
BCG immunisation coverage in the subregion for the 
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corresponding year by creating two trend lines representing 
the country with the highest and lowest BCG coverage 
from 2000 to 2017. To track progress in BCG immunisation 
coverage, the GVAP recommended minimum coverage 
target of 90% was used as the reference standard.8
Estimating DTP3 immunisation coverage
The DTP3 immunisation coverage indicator was defined 
as the percentage of children aged 12–23 months who had 
received DTP3.16 Similar to estimating BCG immunisation 
coverage, we estimated the subregional DTP3 coverage 
trends from 2000 to 2017 by calculating and reporting the 
median, and average coverage weighted by each country’s 
corresponding annual surviving infant population. The 
countries with highest and lowest coverages for each corre-
sponding year were illustrated using different trend lines. To 
track progress in DTP3 immunisation coverage, the GVAP 
recommended minimum DTP3 coverage target of 90% was 
used as the reference standard.8
Estimating immunisation dropout
We determined immunisation dropout rate for each country 
by calculating the proportion of children who dropped out 
from the immunisation system between DTP1 and DTP3,22 
estimated by calculating the percentage coverage of DTP1 
minus DTP3 for each country per year from WUENIC 
data.18 Similarly, we reported trends per country from 2000 
to 2017, and illustrated the median and weighted average 
subregional trend in immunisation dropout, and the corre-
sponding highest and lowest vaccine dropout representing 
the country with the highest and lowest dropout rates. To 
track progress in immunisation dropout, the GVAP recom-
mended maximum dropout rate of 10% was used as the 
reference standard.8
Estimating unvaccinated children
Because the analysis considered West Africa as a single unit, 
we further highlighted the ‘hotspot’ countries where unvac-
cinated children lived in the subregion. We estimated the 
absolute number of unvaccinated children as the propor-
tion of the 2017 country-specific number of surviving 
infants (number of children eligible for DTP3 vaccina-
tion) who did not receive DTP3 in 2017. We illustrated and 
compared this in relation to each country’s overall DTP3 
coverage for the same year using a bubble map.
Estimating inequality in immunisation coverage and dropout
We estimated the most recent situation of intra-country 
inequality in BCG and DTP3 coverage, and immunisa-
tion dropout using a single summary measure of differ-
ence (between the extremes within each dimension of 
inequality) as a proxy for absolute inequality.23 This was 
calculated by subtracting the coverage in one subgroup 
from another defined a priori across the five dimensions 
of inequality adopted from the WHO framework.17 23
Several equity analyses have shown that boys, urban 
dwellers, children of mothers with secondary or higher 
education and those in the richest quintile mostly have 
better access to health services compared with their peers in 
the other extreme.17 23 Thus, for child’s sex, we subtracted 
immunisation coverage for girls from that of boys; for place 
of residence, urban minus rural; for maternal education, 
senior secondary or higher education minus pre-primary 
or none; and region in a country, the region with highest 
coverage minus region with lowest coverage. We used this 
method to estimate the intra-country equity gap for BCG 
and DTP3 immunisation coverages.
To estimate the intra-country equity gap in immunisation 
dropout, the first step was to calculate the immunisation 
dropout rate per subgroup in each of the dimensions; 
for example, we calculated the dropout in the male 
subgroup and female subgroup separately. Following this, 
we computed the difference in immunisation dropout 
between the subgroups similar to the scenario in BCG and 
DTP3 immunisation equity gaps calculation.
Lastly, we displayed and compared the equity gaps for 
BCG, DTP3 and dropout across all five dimensions in the 
subregion using an Equiplot (a plot for equity analysis) 
according to the WHO Health Equity Assessment Toolkit 
Plus.23 To track the equity gap across the five dimensions, 
the GVAP recommended maximum gap of 20% points 
between those in the poorest and richest wealth quintile 
was adopted as the reference standard.8
ReSulTS
Trends in BCg immunisation coverage in West Africa
There was a general trend of increasing BCG immunisa-
tion coverage across West Africa between the year 2000 and 
2017. The median subregional BCG immunisation coverage 
increased from 81% in 2000 to 92% in 2017 (figure 2A). 
The weighted average subregional BCG coverage was 60.7% 
in 2000, peaked at 83.2% in 2009 and was 65.7% in 2017. 
Outlier high-performing countries include Burkina Faso, 
Cabo Verde, The Gambia, Ghana, Senegal and Sierra Leone 
who consistently recorded BCG vaccination coverage of 
greater than 90% since 2010 and contributed to the high 
median BCG immunisation coverage trend in the subre-
gion. Nigeria, on the other hand, consistently recorded the 
lowest subregional BCG immunisation coverage ranging 
from 38% to 76% (average of 52%) between 2000 and 2017. 
The exception to this was in 2011 and 2013 when Niger 
republic had the lowest BCG vaccination coverage in the 
West Africa subregion (online supplementary table 1).
Trends in dTP3 immunisation coverage in West Africa
The median subregional DTP3 coverage increased from 
49% in the year 2000 to 87% in 2017. The subregion 
achieved a median DTP3 coverage of 83% in 2010 when 
the GVAP targets were set. The median subregional DTP3 
coverage has however, plateaued since, with minimal 
yearly increase until 2017 (figure 2C). The weighted 
average subregional DTP3 coverage was 42.3% in 2000, 
peaked at 70.3% in 2009 and was 61.5% in 2017.
Twenty per cent (3/15) of countries in the subre-
gion (Burkina Faso, Cabo Verde and The Gambia) had 
achieved and consistently maintained the GVAP DTP3 
coverage target since 2015 while four additional coun-
tries (Ghana, Senegal, Sierra Leone and Togo) joined in 
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Figure 2 (A)Trends in sub-regional median andaverage weighted Bacillus Calmette-Guerin (BCG) coverage, (B) Number 
of countries achieving the GVAP BCG coverage target (C) Trends in sub-regional median andaverage weighted Diphtheria-
Tetanus-Pertussis 3 (DTP3) containing vaccinecoverage, (D) Number of countriesachieving the GVAP DTP3 coverage target in 
West Africa from 2000 to 2017. Bf=Burkina Faso, Cv= Cabo Verde, Gm= The Gambia, Gn= Guinea, Gh= Ghana, Ni= Nigeria, 
Ng= Niger, Sn= Senegal,Sl=Sierra Leone. Data source:WHO/UNICEF Estimates of National Immunisation Coverage. All graphic 
representation done by authors.
Figure 3 Number of children who did not receive DTP3 per country in West Africa based on the numberof surviving infants in 
2017 and the 2017 DTP3 coverage. The size of the bubbles is proportional to the numberof unvaccinated children in each West 
African country. Date source: Birth cohort data (United Nations populationestimates, 2017 revision), DTP3 coverage (WUENIC). 
All graphic representationdone by authors.
2017 (figure 2D). In contrast, Guinea, Mali and Nigeria 
consistently had the lowest DTP3 coverage trends in the 
subregion (online supplementary table II).
unvaccinated children in West Africa
There were an estimated 5 051 668 children who did 
not receive DTP3 vaccination in the 15 West African 
countries in 2017. Most of these children, 3 957 966 
(78.3%), lived in Nigeria which accounted for 52.3% 
of the subregional 13 111 000 surviving infants in 2017. 
Countries with high DTP3 coverage typically had the 
lowest absolute numbers of unvaccinated children in 
the subregion compared with countries with low DTP3 
coverage (figure 3).
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Figure 4 (A) Trends in dropouts from 1st dose ofDiphtheria-Pertussis-Tetanus-containing vaccine to 3rd dose of Diphtheria-
Pertussis-Tetanus-containing vaccine (DTP1-DTP3), (B) Number of countries achieving the GVAP dropout target across West 
Africa. Bf= Burkina Faso, Bn= Benin, Ci= Coted’Ivoire, Gh= Ghana, Gm= The Gambia, Gn= Guinea, Li= Liberia,Ml= Mali, 
Si= Sierra Leone. Data source: WHO/UNICEFEstimates of National Immunisation Coverage. All graphic representation done 
byauthors.
Immunisation dropout rate: trends in dTP1–dTP3 dropout 
across West Africa
Subregional DTP1–DTP3 dropouts reduced from a 
median of 16.4% in 2000 to 7.4% in 2017, meeting and 
maintaining the GVAP target of <10% dropout rate since 
2008 (figure 4A). The weighted average subregional 
immunisation dropout mirrored the median subregional 
trends. Overall, countries with high DTP3 coverage main-
tained a low dropout below the recommended target. 
Burkina Faso, Cabo Verde and The Gambia consistently 
maintained dropout rate below 10% since 2005.
Four countries in the subregion (Cote d’Ivoire, Guinea, 
Liberia and Niger) consistently failed to meet the GVAP 
target of <10% dropout throughout the period under 
review (Figure 4B and online supplementary table 3). 
Nigeria which consistently had the lowest DTP3 coverage 
during the period under review, however, maintained a 
DTP1–DTP3 dropout of 10% and below since 2006.
equity gaps in BCg immunisation coverage
The equity gap in BCG immunisation coverage in-country 
was more than the recommended 20% points or more in 
Cote d’Ivoire, Guinea, Mali and Nigeria across all equity 
dimensions except for sex (figure 5A). These same coun-
tries typically had the lowest BCG coverages across the 
subregion (online supplementary table 4). Contrast-
ingly, The Gambia, Ghana and Sierra Leone with high 
BCG coverages of more than 95% had the narrowest 
equity gaps of less than 20% points across all dimensions 
(figure 5A, online supplementary table 4). Overall, the 
gender of children and location of residence (urban or 
rural) seemed to contribute minimally to inequalities in 
BCG immunisation coverage in the subregion compared 
with other dimensions (figure 5A).
equity gaps in dTP3 immunisation coverage
The equity gap in DTP3 was highest and more than 
20% points in Guinea, Mali, Niger and Nigeria across 
all dimensions except for child’s sex (figure 5B). Again, 
similar to the pattern seen in the equity gaps in BCG 
immunisation coverage, the countries with very wide 
equity gap also had low DTP3 immunisation coverage 
compared with other countries in the subregion. 
Furthermore, countries with high DTP3 coverage also 
had narrow equity gap across all dimensions (online 
supplementary table 5). Overall, the inequality in 
DTP3 coverage in most countries was mainly related 
to equity gaps of more than 20% points between the 
wealthiest and the poorest, high coverage regions and 
low coverage regions, and between children of mothers 
with at least secondary education and those with no 
formal education (figure 5B).
equity gaps in dropout rates (dTP1–dTP3 dropout)
Overall, those living in urban areas, those in regions with 
the highest coverage, those in the wealthiest quintile and 
those with maternal secondary education or more had 
lower DTP1 to DTP3 dropouts compared with the other 
extreme. The exception was in Nigeria and Guinea where 
the children from the ‘most advantaged’ backgrounds 
had wider DTP1 to DTP3 dropout compared with the 
children from the ‘most disadvantaged’ backgrounds. 
Equity gaps in immunisation dropout rates were gener-
ally narrower compared with those in BCG and DTP 
coverage (figure 5C).
dISCuSSIon
There is no doubt that significant progress has been made 
in improving vaccination coverage by immunisation systems 
across the subregion. This progress should, however, be 
interpreted cautiously. Although we found an increasing 
trend of vaccination coverage in the subregion, significant 
inter-country variations remain. The increase in weighted 
average subregional BCG and DTP3 coverage has stalled 
since 2009, falling below the GVAP DTP3 coverage target. 
For example, Burkina Faso, Cabo Verde and The Gambia, 
which have consistently maintained national DTP3 coverage 
above the GVAP recommendation since 2015, cumulatively 
account for less than one-tenth of the total population of 
surviving infants in the subregion who are eligible for DTP3 
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Figure 5 Multi-dimensional equity gaps in (A) BCG coverage, (B) DTP3 coverage and (C) DTP1-DTP3 immunisation dropout 
in the ‘most disadvantaged’ compared to the‘most advantaged’ children per country across West Africa. Cabo Verde’s 
immunisation data wasnot disaggregated by family wealth status. The latest available nationally representative DHS or 
MICS survey data used per country. Benin (MICS 2014), Burkina Faso (DHS 2010), CaboVerde (DHS 2005), Cote d’Ivoire 
(MICS 2016), Gambia (DHS 2013), Ghana (DHS2014), Guinea (MICS 2016), Guinea Bissau (MICS 2014), Liberia (DHS 2013), 
Mali(MICS 2015), Niger (DHS 2012), Nigeria (MICS 2016/17), Senegal (DHS 2017), Sierra Leone (MICS 2017), Togo (DHS 
2013/14). All graphic representation done by authors.
immunisation. These highly successful countries, therefore, 
masked the trends in the relatively poor performing coun-
tries and impacted significantly on the increasing median 
subregional coverage trends. This highlights the need for 
weighted averages at subregional levels and to avoid relying 
solely on medians at subregional or macro-level.
In our study, three countries, Guinea, Mali and Nigeria, 
accounting for >60% of the subregional surviving infant 
population eligible for DTP3 immunisation in 2017 
persistently had the poorest and stagnant coverage trends. 
This is historically similar to findings in other reports from 
the West Africa subregion24 and WHO Afro region.25 26 
These three countries are consistently ranked low on the 
Human Development Index (HDI), with both Mali and 
Guinea ranked among the 10 lowest countries in Africa 
on the 2016 HDI.27 All three countries have experienced 
repeated armed conflict over the past decade, in addi-
tion to specific issues such as the 2014 Ebola outbreak in 
Guinea, and a huge rural, nomadic and sparsely distrib-
uted terrain in Mali. Nigeria is the only country in Africa 
yet to be certified polio-free highlighting critical issues 
which impacted negatively on immunisation and routine 
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health systems functions.28 These countries, therefore, 
harbour a large population of unvaccinated children and 
a cluster of the most vulnerable populations in the subre-
gion, many of whom are continually being excluded from 
lifesaving interventions and are systematically missed or 
‘left behind’ by immunisation systems.
Furthermore, there is a correlation between immuni-
sation programme performance and the routine health 
system in which it functions. Poor immunisation system 
performance often highlights underlying structural 
weaknesses in the health system in which it operates.29 
Issues of poorly financed health systems,30 31 demo-
tivated human resource for health32 and poor plan-
ning for immunisation within the wider context of the 
health system33 have been reported in Mali, Guinea and 
Nigeria as contributory to poor coverages and dropout. 
However, the above factors can only partially explain the 
poor performance in these countries, as other relatively 
well-performing countries in the subregion also grapple 
with similar challenges.
Cabo Verde, Burkina Faso and The Gambia can be 
considered as ‘outlier’ highly successful countries in 
West Africa as they have consistently maintained DTP3 
coverage above 90% since 2015 and dropout rate below 
10% since 2005. The fact that these countries rank low 
in the HDI such as Guinea, Mali and Nigeria suggest that 
other context-specific issues determine the high childhood 
vaccination coverage and low dropout in these setting. 
The Gambia and Cabo Verde, for example, are relatively 
small countries, the majority of the population live within a 
convenient distance from a health facility, and the govern-
ment routinely provide immunisation services via ‘trekking’ 
(out-reach) clinics which could partly explain the success 
of their immunisation system.34 Organisation of the health 
system with systematic outreach immunisation clinics has 
also been reported in Burkina Faso as contributory to its 
successful immunisation system.35
The subregional median and weighted average immu-
nisation dropout rate progressively fell and maintained 
values well below the accepted GVAP target of at most 
10% almost a decade before 2017. Overall, countries 
in the subregion with high temporal vaccine coverage 
trends generally had lower dropout rate between DTP1 
and DTP3 highlighting the consistency and resilience 
of their immunisation systems to reach a child multiple 
times with the same antigen. This specific finding, thus, 
suggests that improving overall vaccination coverage 
and strengthening routine immunisation may be key in 
reducing vaccination dropouts.
The fact that Nigeria, with consistently poor and stag-
nant DTP3 coverage trends between 2000 and 2017 
nevertheless achieved the GVAP target of <10% dropout 
between DTP1 and DTP3 since 2010 is an interesting 
finding, which should be viewed with caution. While the 
country may have been effective in delivering multiple 
antigens consistently, and retaining infants within its 
immunisation system, it may be systematically leaving 
behind a cluster of the most vulnerable infants who may 
never interface with the immunisation system. In this 
landscape, achieving the GVAP targets and appropriate 
coverage needed to provide indirect protection may be a 
mirage with an ever-present risk of VPDs outbreak if clear 
and consistent efforts are not initiated and sustained.
Beyond adequate vaccination coverages, achieving 
equity in national immunisation systems is a key focus 
of Gavi’s strategy for 2016–2020.36 Our study showed 
that Guinea, Mali and Nigeria with the lowest BCG and 
DTP3 coverages trends in the West African subregion 
also had the widest equity gaps across all measured 
dimensions of inequality. If countries in the subregion 
aim to achieve the GVAP immunisation coverage targets 
by 2020, this scenario of children who face multiple 
socioeconomic disadvantages and are potentially being 
left behind by immunisation systems must be halted 
and reversed.
The first step towards overcoming inequalities requires 
reliable evidence about those who are excluded in 
order to inform the delivery of equitable and efficient 
services.37 Similar to previous findings,38 39 our analysis 
showed that generally, the most substantial equity gaps 
in vaccine coverage and dropouts across West African 
countries were mostly related to poverty, low maternal 
education and living in certain regions in a country. 
Differential coverage between the most advantaged and 
the most disadvantaged subgroup in most countries was 
significantly more than the recommended 20% points, 
Gavi’s wealth-based benchmark for monitoring equity in 
vaccination.40 A child’s sex and place of residence in a 
rural or urban setting minimally influenced differences 
in vaccine coverage.
Many equity analyses including the GVAP targets use only 
wealth-based measure of inequality to measure gaps in vacci-
nation uptake. We argue that this may not sufficiently reflect 
the complexities of social exclusion as inequalities manifest 
in manifold equally important dimensions as shown in this 
analysis. Systematic exposure to negative, multidimensional 
and overlapping socioeconomic determinants significantly 
limit the probability of families to surmount disadvantages, 
access preventative interventions and ultimately puts them 
at greater risk of poor health outcomes.37
Central to the targets of the GVAP, the aspirational goals 
of Universal Health Coverage (UHC), and the post-2015 
Sustainable Development Goals (SDGs) are to ensure 
health and well-being for all and to reduce inequalities. 
Ensuring that every child born in West Africa, no matter 
which country they live in, or their socioeconomic back-
ground access and complete their recommended vacci-
nations is critical to meeting these GVAP, UHC and SDG 
targets. Governments, implementing and developments 
partners in the subregion should, therefore, design inter-
ventions targeted at the populations who are currently 
being left behind and reduce the barriers to immunisa-
tion to ensure that their needs are not masked behind 
subregional and national averages. This is even more so as 
DTP3 coverage though recommended by WHO is a rather 
conservative measure of coverage given that antigens like 
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measles are only given post this point and remain crucial 
given the resurgence of these diseases globally. In addition, 
birth cohorts in these countries may be underestimated 
making the estimates of coverage overestimates.
Overall, there are important critical lessons to be 
learnt from the findings reported here. First, if the West 
Africa subregion is to improve the current realities and 
overcome the stalling DTP3 coverage, challenges in 
increasing vaccination coverage need to be addressed 
at subnational and national levels in a context-specific 
manner due to varying coverages across the subregion. 
Second, countries with low coverages in the subregion 
looking to strengthen their immunisation systems could 
adopt useful lessons from their peers in West Africa 
who have achieved the GVAP targets and have consis-
tently maintained increasing coverage. Furthermore, 
continued commitment and investment in the coun-
tries with persistently high coverages will be pivotal in 
ensuring that the hard-won gains are maintained. This 
remains even more critical with some Gavi eligible coun-
tries scheduled for graduation from Gavi support in the 
coming years. Lastly, the stagnant subregional DTP3 
coverage since 2009 highlights the point that efforts at 
improving coverage may yield more obvious immediate 
results at low coverage levels and as coverage increases, 
more significant high-level commitment and in-country 
ownership will be needed to reach the last child.41
There are inherent limitations to our study. First, 
our analysis did not consider the temporal impact of 
economic growth trajectory (measured by gross domestic 
product) and immunisation financing on the vaccine 
coverage trends and dropout presented here. There is no 
doubt that external donor funding such as from Gavi and 
government expenditure on immunisation, depended 
on economic growth, impact vaccine coverage trends. 
Further research on vaccine coverage in the West Africa 
subregion could explore this dimension which would 
provide a more nuanced interpretation of the evidence. 
Second, the inter-country equity comparison should be 
taken carefully because the national survey data used in 
our analysis were from varying years. Although the meth-
odology for MICS and DHS are considered similar, the 
fact that the data compared are from the latest surveys 
done in different years across countries limit the extent 
to which direct comparison may be made. In addition, 
the DHS and MICS surveys rely on parental recall and 
vaccine card record to determine vaccination status; 
thus, responses could be affected by recall and ascertain-
ment bias. While we acknowledge the limitations of the 
national surveys, they represent the best available popula-
tion-based data covering all regions within the countries 
studied, thus allowing their findings to be generalisable.
Lastly, the five socioeconomic determinants used in 
the multidimensional equity analysis overlap in an indi-
vidual and are interdependent. For example, an uned-
ucated mother is likely to be poor and be clustered in a 
disadvantaged region. It may be important to state that 
our study’s aim was not to argue causality between the 
equity dimensions and vaccine uptake. Rather, it was 
to provide an alternative dashboard to monitor equity 
in immunisation in addition to differences in wealth 
quintile alone currently used by GVAP. We acknowledge 
that important equity gaps may be missed by comparing 
only the extremes within a dimension of equity and not 
among other subcategories, for example, between wealth 
quintiles 2 and 3. However, our approach highlights the 
equity gaps between the most advantaged and most disad-
vantaged population, and in this way, it is easy to compare 
the extremes of circumstances of inequality.
ConCluSIonS
Our study shows that the West African subregion has 
made significant strides between 2000 and 2017 in 
ensuring that its children access and use immunisation. 
However, despite initial rapid progress, BCG and DTP3 
coverage have stalled over the last decade in most coun-
tries across the subregion, with an unlikely trajectory of 
achieving the GVAP targets on coverage, dropouts and 
equity. Furthermore, in underperforming countries, 
wide intra-country equity gaps in vaccine coverage and 
dropouts mainly related to maternal education, wealth 
and region of residence exist between the most advan-
taged and the most disadvantaged children.
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